| __timestamp | Eli Lilly and Company | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 2652041 |
| Thursday, January 1, 2015 | 6533000000 | 2361587 |
| Friday, January 1, 2016 | 6452000000 | 4472869 |
| Sunday, January 1, 2017 | 6588100000 | 5030957 |
| Monday, January 1, 2018 | 5975100000 | 4988941 |
| Tuesday, January 1, 2019 | 6213800000 | 5196412 |
| Wednesday, January 1, 2020 | 6121200000 | 6652774 |
| Friday, January 1, 2021 | 6431600000 | 18418247 |
| Saturday, January 1, 2022 | 6440400000 | 24827066 |
| Sunday, January 1, 2023 | 6941200000 | 41896408 |
| Monday, January 1, 2024 | 8593800000 | 15488619 |
Unleashing insights
In the world of pharmaceuticals, managing costs is as crucial as innovation. Eli Lilly and Company, a stalwart in the industry, has consistently maintained its Selling, General, and Administrative (SG&A) expenses around $6.4 billion annually over the past decade. This stability reflects a strategic balance between operational efficiency and market expansion. In contrast, Opthea Limited, a smaller player, has seen its SG&A expenses grow significantly, from approximately $2.7 million in 2014 to over $41 million in 2023. This represents a staggering increase of over 1,400%, highlighting Opthea's aggressive growth strategy and investment in market presence. While Eli Lilly's expenses peaked in 2023, Opthea's fluctuating costs suggest a dynamic approach to scaling operations. This comparison underscores the diverse strategies companies employ to navigate the competitive pharmaceutical landscape.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Xencor, Inc.
Comparing SG&A Expenses: Sanofi vs Opthea Limited Trends and Insights
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Genmab A/S and Opthea Limited: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Pharming Group N.V. and Opthea Limited
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited